Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2020) 70 AEP957 | DOI: 10.1530/endoabs.70.AEP957

ECE2020 Audio ePoster Presentations Thyroid (144 abstracts)

A novel method for detecting autoantibody to wd repeat domain 1: Clinical application for differentiating papillary thyroid carcinoma with poor clinical outcome

Shoichiro Izawa 1,1 , Kazuhiko Matsuzawa 1 , Kazuhisa Matsumoto 1 , Kenji Fukaya 1 , Takahiro Fukuhara 2 , Makoto Wakahara 3 , Atsuro Koga 4 , Tomoya Hino 5 & Kazuhiro Yamamoto 1


1Tottori University Faculty of Medicine, Division of Cardiovascular Medicine, Endocrinology and Metabolism, Yonago, Japan; 2Tottori University Faculty of Medicine, Division of Otolarygology, Head and Neck Surgery, Yonago, Japan; 3Tottori University Faculty of Medicine, Division of General Thoracic Surgery, Yonago, Japan; 4Tottori University, Organization for Research Initiation and Promotion, Tottori, Japan; 5Tottori University, Department of Chemistry and Biotechnology, Graduate School of Engineering, Tottori, Japan


Background: Papillary thyroid carcinoma (PTC) is known as the most common histological subtype of thyroid carcinoma. The prognosis of PTC is generally favorable. However, small number of patients with PTC progressed with distant metastasis and invasion to adjacent organs. New diagnostic tool for early detection of PTC with poor outcome is desired. We previously reported that autoantibody to WD repeat domain 1 (AWA) in the serum was associated with the existence of undifferentiated thyroid carcinoma (UTC) and PTC (Izawa S et al., Clin Endocrinol 2013). The objective of our study is todevelop this assay to be sensitive and specific for differentiating PTC with poor prognosis.

Materials and methods: A peptide library (peptide length = 12 aa, off-set = 6 aa) originated from human WDR1 isoform 1 were firstly screened (1st screening) by the serum of 3 patients with UTC and 3 normal healthy controls (N). Furthermore, 2nd screening was performed for selecting candidate peptides by using another peptide library (peptide length = 12 aa, off-set = 2 aa) designed by the result of 1st screening. Finally, candidate peptides were evaluated to be hydrophilic by bioinformatics. Sera from 16 patients with advanced thyroid carcinoma (UTC and PTC with metastasis and/or invasion to adjacent organs), 8 with not advanced PTC (without metastasis and invasions to adjacent organs), 14 with benign thyroid nodules (B), 15 with autoimmune thyroid disease (A), and 7 N were evaluated by ELISA using 12 candidate peptides.

Results: A total number of 42 peptides for detecting high titer of AWA were selected by the 1st screening. Most of these peptides were located in the C terminal of WDR1 isoform 1. After finishing 2nd screening, 12 candidate peptides with hydrophilic sequences were selected for ELISA. A peptide originating from human WDR1 isoform 1 (WDR1 2–33) presented significantly higher (P < 0.05) titer of AWA in advanced thyroid carcinoma (0.621 ± 0.289) than not advanced PTC (0.326 ± 0.114), B (0.255 ± 0.142), A (0.318 ± 0.164), and N (0.303 ± 0.161). The diagnostic performance of WDR1 2–33 was superior to other 11 peptides by ROC analysis.

Conclusion: We demonstrated that WDR1 2–33 could be a peptide containing the epitope of AWA. Our data suggested that evaluating AWA by WDR1 2–33 might be a new diagnostic method for early diagnosis of PTC with poor prognosis (patent pending JP2018–045806).

Volume 70

22nd European Congress of Endocrinology

Online
05 Sep 2020 - 09 Sep 2020

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.